Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | P2RY2 | P41231 | 15/20 | 0.80 |
| ▸ | SLC28A1 | O00337 | 1/20 | 0.78 |
| ▸ | SLC28A2 | O43868 | 1/20 | 0.78 |
| ▸ | SLC29A1 | Q99808 | 1/20 | 0.78 |
| ▸ | SLC28A3 | Q9HAS3 | 1/20 | 0.78 |
| ▸ | P2RY6 | Q15077 | 10/20 | 0.74 |
| ▸ | P2RY4 | P51582 | 8/20 | 0.73 |
| ▸ | P2RY14 | Q15391 | 2/20 | 0.69 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Uridine SCHEMBL4308217 | 1.00 | P2RY2 (0.80) | P2RY2SLC28A1SLC28A2SLC29A1SLC28A3 | |
| Uridine SCHEMBL15321443 | 1.00 | P2RY2 (0.80) | P2RY2SLC28A1SLC28A2SLC29A1SLC28A3 | |
| Uridine SCHEMBL28456453 | 0.99 | P2RY2 (0.79) | P2RY2SLC28A1SLC28A2SLC29A1SLC28A3 | |
| Uridine SCHEMBL28898119 | 0.99 | P2RY2 (0.79) | P2RY2SLC28A1SLC28A2SLC29A1SLC28A3 | |
| Uridine SCHEMBL29482406 | 0.99 | P2RY2 (0.79) | P2RY2SLC28A1SLC28A2SLC29A1SLC28A3 | |
| Uridine SCHEMBL29077342 | 0.98 | P2RY2 (0.77) | P2RY2SLC28A1SLC28A2SLC29A1SLC28A3 | |
| Uridine SCHEMBL4244 | 0.95 | SLC28A1 (0.81) | P2RY2SLC28A1SLC28A2SLC29A1SLC28A3 | |
| Uridine SCHEMBL30293967 | 0.95 | SLC28A1 (0.81) | P2RY2SLC28A1SLC28A2SLC29A1SLC28A3 | |
| Uridine SCHEMBL30205276 | 0.95 | P2RY2 (0.73) | P2RY2SLC28A1SLC28A2SLC29A1SLC28A3 | |
| Uridine SCHEMBL28201123 | 0.94 | P2RY2 (0.77) | P2RY2SLC28A1SLC28A2SLC29A1SLC28A3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 14 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250345353-A1 | COMPOUNDS AND METHODS FOR TREATING NEUROLOGICAL AND CARDIOVASCULAR CONDITIONS | ASTROCYTE PHARMACEUTICALS INC (US) | 2025-11-13 | — | — | US | disclosed |
| US-12390483-B2 | Compounds and methods for treating neurological and cardiovascular conditions | ASTROCYTE PHARMACEUTICALS, INC. (US) | 2025-08-19 | — | — | US | disclosed |
| US-20250177405-A1 | METHODS OF TREATING NEUROLOGICAL AND CARDIOVASCULAR CONDITIONS | ASTROCYTE PHARMACEUTICALS, INC. | 2025-06-05 | — | — | US | disclosed |
| US-12239654-B2 | Compounds and methods for treating neurological and cardiovascular conditions | ASTROCYTE PHARMACEUTICALS, INC. (US) | 2025-03-04 | — | — | US | disclosed |
| EP-4436567-A1 | METHODS OF TREATING NEUROLOGICAL AND CARDIOVASCULAR CONDITIONS | Astrocyte Pharmaceuticals, Inc. (US) | 2024-10-02 | — | — | EP | disclosed |
| EP-4414027-A2 | COMPOUNDS AND METHODS FOR TREATING NEUROLOGICAL AND CARDIOVASCULAR CONDITIONS | Astrocyte Pharmaceuticals, Inc. (US) | 2024-08-14 | — | — | EP | disclosed |
| EP-3445368-B1 | COMPOUNDS AND METHODS FOR TREATING NEUROLOGICAL AND CARDIOVASCULAR CONDITIONS | ASTROCYTE PHARMACEUTICALS INC (US) | 2024-07-17 | — | — | EP | disclosed |
| US-11839615-B2 | Compounds and methods for treating addiction and related disorders | ASTROCYTE PHARMACEUTICALS, INC. (US) | 2023-12-12 | — | — | US | disclosed |
| US-20230165887-A1 | COMPOUNDS AND METHODS FOR TREATING NEUROLOGICAL AND CARDIOVASCULAR CONDITIONS | THE BOARD OF REGENTS OF THE UNIVERSITY OF TEXAS SYSTEM | 2023-06-01 | — | — | US | disclosed |
| WO-2023091791-A1 | METHODS OF TREATING NEUROLOGICAL AND CARDIOVASCULAR CONDITIONS | ASTROCYTE PHARMACEUTICALS, INC. (US) | 2023-05-25 | — | — | WO | disclosed |
| US-11484545-B2 | Compounds and methods for treating neurological and cardiovascular conditions | ASTROCYTE PHARMACEUTICALS, INC. (US) | 2022-11-01 | — | — | US | disclosed |
| US-20220305044-A1 | COMPOUNDS AND METHODS FOR TREATING NEUROLOGICAL AND CARDIOVASCULAR CONDITIONS | THE UNITED STATES OF AMERICA, AS REPRESENTED BY THE SECRETARY, DEPARTMENT OF HEALTH AND HUMAN SERVICES | 2022-09-29 | — | — | US | disclosed |
| CN-114903903-A | Compounds and methods for treating neurological and cardiovascular conditions | 阿斯特罗赛特制药公司 | 2022-08-16 | — | — | CN | disclosed |
| CN-109310695-B | Compounds and methods for treating neurological and cardiovascular conditions | 阿斯特罗赛特制药公司 | 2022-04-01 | — | — | CN | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12390483-B2 | Compounds and methods for treating neurological and cardiovascular conditions | TNNI3, CPT1B, TNNT2 | P2RY2 1796/4885SLC28A1 1459/4885SLC28A2 1402/4885 |
| US-11839615-B2 | Compounds and methods for treating addiction and related disorders | ADORA2A, TAAR5, ADORA3 | P2RY2 119/4885SLC28A1 345/4885SLC28A2 315/4885 |
| US-20250345353-A1 | COMPOUNDS AND METHODS FOR TREATING NEUROLOGICAL AND CARDIOVASCULAR CONDITIONS | TNNI3, CPT1B, TNNT2 | P2RY2 1796/4885SLC28A1 1459/4885SLC28A2 1402/4885 |
| US-11484545-B2 | Compounds and methods for treating neurological and cardiovascular conditions | TNNI3, CPT1B, TNNT2 | P2RY2 1796/4885SLC28A1 1459/4885SLC28A2 1402/4885 |
| US-20220305044-A1 | COMPOUNDS AND METHODS FOR TREATING NEUROLOGICAL AND CARDIOVASCULAR CONDITIONS | TNNI3, CPT1B, TNNT2 | P2RY2 1796/4885SLC28A1 1459/4885SLC28A2 1402/4885 |
| US-20250177405-A1 | METHODS OF TREATING NEUROLOGICAL AND CARDIOVASCULAR CONDITIONS | ADORA2A, ADORA3, ADORA1 | P2RY2 9/4885SLC28A1 146/4885SLC28A2 144/4885 |
| US-12239654-B2 | Compounds and methods for treating neurological and cardiovascular conditions | TNNI3, CPT1B, TNNT2 | P2RY2 1796/4885SLC28A1 1459/4885SLC28A2 1402/4885 |
| US-20230165887-A1 | COMPOUNDS AND METHODS FOR TREATING NEUROLOGICAL AND CARDIOVASCULAR CONDITIONS | TNNI3, CPT1B, TNNT2 | P2RY2 1796/4885SLC28A1 1459/4885SLC28A2 1402/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.